Skip to main content

Immune Response BioPharma, Inc.

Home
Drug Discovery
Press Releases
Investor Relations
Royalties
Stock Information
Executive Team
Scientific Board
Clinical Trials
REMUNE Vaccine
REMUNE Rx Co-pay Card
REMUNE FULL PRESCRIBING
REMUNEX Vaccine
Remune Pediatric
RemuneVax Vaccine
NeuroVax Vaccine
NeurOral
RAVAX Vaccine
RAVAX II Vaccine
Zorcell Vaccine
DermaVax
Immunereszumab
Sepsicillin
Rare Diseases
Alliances
Vaccines Direct
Partnering
Bio Defense
Immune Response Hospital
Orchestra Therapeutics
Research Donations
About Us
Corporate Filings
Corporate ByLaws
Transfer Agent
Employment
Events
Webcast
Contact Us
Email Alerts
Member Login
Site Map

Immune Response BioPharma, Inc. TM 

© 

2010-2018 


Scientific Advisory Board: 

undefined

Scientific Advisory Board: for Multiple Sclerosis & NeuroVax TM   

 

 

The Scientific Advisory Board guiding the development of NeuroVax (TM) consists of four initial members:

Dr. Dennis Bourdette: is Chair and the Roy and Eulalia Swank Research Professor in the Department of Neurology at Oregon Health and Science University (OHSU), where he has been a faculty member since 1983. He was the lead clinician investigator on the early trials of TCR peptide vaccination in MS. Dr. Bourdette has published numerous articles related to MS and is listed in the Best Doctors in America.

 

 

Dr. Arthur Vandenbark: is a senior research career scientist at the Portland Veterans Affairs Medical Center, and a professor in the Departments of Neurology and Molecular Microbiology and Immunology at OHSU. An inventor and pioneer of the TCR peptide vaccination approach for MS, Dr. Vandenbark is the recipient of the Javits Neuroscience Investigator Award. He has published numerous articles in the area of MS and its animal models & helped develop the FOXP3+ Expression technology the mechanism of action for NeuroVax.

 

 

Dr. Halina Offner: is a Professor in the Department of Neurology at Oregon Health & Science University (OHSU) in Portland, Oregon with a joint appointment in the Department of Anesthesiology and Peri-Operative Medicine. She joined the faculty at OHSU. In 1984 & Dr. Offner was awarded the prestigious Javits Neuroscience Investigator Award in 1994 for her nationally and internationally recognized work in the neurosciences. Dr. Offner’s research interests include multiple sclerosis, experimental autoimmune encephalomyelitis (EAE), influence of sex hormones on autoimmunity, neuroimmunology, and stroke. Dr. Offner also contributed to the development of the FOXP3+ Expression technology. Her work is extensively published, with over 250 articles and book chapters in press.

 

 

Dr. Richard Bartholomew: is an industry veteran with over 30 years’ of experience in developing treatments for Auto-Immune diseases. He earned his PhD in Biochemistry/Immunology at the University of Utah Medical Center and has led the AI program including the development of NeuroVax for Immune Response as VP of R&D. Additionally Dr. Bartholomew helped co-develop the FOXP3+ Expression technology the mechanism of action for NeuroVax.

 

 


undefined
Immune Response BioPharma, Inc. TM  

Copyright © 2010-2018            www.immuneresponse.net       All Rights Reserved